What clinical factors impact the likelihood of a patient receiving an allogeneic transplant? @msorror @ASTCT #ToxicitiesConference24
Impressive response data for #TIL in #NSCLC @DrBetofMDPhD @ASTCT #ToxicitiesConference24 Next, can we eliminate IL-2? 🧯🔥
Dr. Reena Thomas from Stanford - TIAN: Tumor inflammation-associated neurotoxicity, observed in CAR T cell therapy for GBM 🧠, distinct from ICANS due to neuroanatomical region specificity @ASTCT #ToxicitiesConference24
Here we go! @BrianShafferMD leading us through the morning session addressing controversies re: #PTCy. Dose? Alternatives? Toxicities? @ASTCT #ToxicitiesConference24
What will change in administration to #POTUS47 mean for #telemedicine 💻coverage in 2025? Dr. Sarah Wall from OSU is asking the tough questions.🤔
@ASTCT
#ToxicitiesConference24 Will common sense prevail?
~50% subsequent admission rate for initial grade 1 outpatient CRS management - Mayo experience presented by Dr. Yi Lin. #ASTCT #ToxicitiesConference24
Muscles matter! 💪 Sarcopenia and CAR T outcomes #ToxicitiesConference24